Aktienanalyse zu Intuitive Surgical Inc (ISRG)ISRGIntuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc is a good buy right now due to its current price of $423.96 being below analyst targets of $485 and $500, indicating significant upside potential. The company has shown a strong revenue growth of 20.5% year-over-year, with a robust gross margin of 67.78% in the latest quarter, suggesting solid profitability. However, a risk to consider is the RSI at 74.78, indicating that the stock may be overbought in the short term.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.